The role of Souvenaid® in the management of patients with early Alzheimer’s disease including mild cognitive impairment.

Link copied!

For the management of patients with early Alzheimer’s disease.

Key takeaways

  • Souvenaid® is a medical food proven to slow decline in memory and cognition in early Alzheimer’s disease when taken daily for at least 6 months.1-3
  • Benefits have been shown in 3 RCT’s in MCI [Prodromal AD]/Mild AD.1-3
  • Souvenaid® is well tolerated and has a positive safety profile.1-3
  • Souvenaid® is best used in the earliest stages of disease.1-3

In this 5 minute lecture, Associate Professor Michael Woodward discusses the evidence for the medical food Souvenaid® and its role in the management of patients with early Alzheimer’s disease including mild cognitive impairment.

Was this helpful?
0 0
References
  1. Scheltens P, et al. Alzheimers Dement 2010; 6: 1–10.e1
  2. Scheltens P, et al. J Alzheimers Dis 2012; 31: 225–236
  3. Soininen H, et al. Alzheimer’s Dement. 2021;17:29–40